Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1356 BS dose-ranging study in type 2 diabetes
2006-002311-27Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of linagliptin in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Change in HbA1c from baseline to 12 weeks. Started Aug 2006; status: completed.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2006-002311-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002311-27.